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Abstract: Abacavir has been at the center of research and clinical interest in the last two years. 
The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially 
since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in 
HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; 
the possible increased risk of myocardial infarction after recent exposure to abacavir has been 
debated; and the drug has been moved from the “recommended” category to the “alternative” 
category in several guidelines. Still, the drug remains a useful agent in combination with other 
drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the 
pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, 
including a thorough review of all of the recent studies relevant to both drugs.
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Introduction/background
It has been more than 20 years since the introduction of the first antiretroviral (ARV) drug 
zidovidine (AZT, ZDV). Early ARV therapy regimens required patients to take many 
pills per dose multiple times per day, which often led to poor adherence and treatment 
failure. It is thus of no surprise that in later years, simplified regimens (fixed dose combi-
nations, FDCs) have emerged. Current recommendations suggest starting treatment-naïve 
patients on 2 nucleoside reverse transcriptase inhibitors (NRTIs) with either a protease 
inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI).1 One such 
NRTI combination is abacavir (ABC) and lamivudine (3TC) which is also available as 
a FDC. This article provides a comprehensive review of these two drugs.
Abacavir (ABC)
Abacavir is available as a single-agent, in dual combination with lamivudine 
(Epzicom®; ViiV Healthcare), and as a triple combination with zidovudine and lami-
vudine (Trizivir®; ViiV Healthcare). A generic form, abacavir sulfate is also available. 
The recommended adult dose of ABC is 300 mg twice daily or 600 mg once daily. 
No dose adjustment is required for renal dysfunction.1
Chemistry and pharmacodynamics
Abacavir is a synthetic carbocyclic nucleoside analogue of the purine, guanine. It is 
converted to the active metabolite carbovir triphosphate (CBV-TP) through a three-step 
phosphorylation and deamination process by intracellular enzymes. The active metabolite Therapeutics and Clinical Risk Management 2010:6 84
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CBV-TP is an analog of deoxyguanosine-5-triphospahte 
(dGTP), which competes with the endogenous dGTP and 
blocks its incorporation into the HIV viral DNA. This results 
in termination of chain elongation and inhibition of viral 
replication.
Pharmacokinetics
Abacavir is rapidly absorbed and is widely distributed. It has 
good bioavailability, (approximately 83%). Abacavir has 
significant penetration into cerebral spinal fluid (CSF)2,3 and 
has been recovered in the semen.4 Mean time to peak after 
single or multiple oral dosages is 0.7 to 1.7 hours. Approxi-
mately 50% of the drug binds to human plasma proteins. 
The primary route of elimination of ABC is metabolism by 
the two hepatic enzymes alcohol dehydrogenase (ADH) and 
glucuronyl transferase (GT). Alcohol dehydrogenase metabo-
lizes approximately 36% of the dose to inactive carboxylate 
and GT metabolises approximately 30% of the dose to inac-
tive glucuronide metabolite. Although ABC is metabolized 
by the liver, it does not inhibit or induce cytochrome P-450 
(CYP-450) enzymes and therefore does not interact with 
medications metabolized by this system.2 Eighty-three per-
cent of the dose of the drug is excreted primarily in the urine 
as metabolites, about 2% as unchanged drug; 66% of the dose 
is excreted as the two major metabolites, the 5’-carboxylate 
and the 5’-glucuronide.2
The serum half-life of elimination (t1/2) is about 1.5 hours 
but the drug has been shown in a number of pharmacokinetic 
and clinical studies to be efficacious when administered 
once daily.5–9 This is because the activity and efficacy of the 
drug is mainly determined by its intracellular concentration. 
When ABC is converted intracelluarly to CBV-TP, the phos-
phorylation process essentially results in entrapment of the 
active metabolite in the cell leading to higher accumulation 
of the active agents than is achieved in the serum. Thus, the 
concentration of the active drug intracelluarly is higher than 
that measured in the serum.6 As the frequency of drug admin-
istration is closely related to the pharmacokinetic properties 
of a drug, the key parameter is the half-life. However, the 
serum T1/2 of ABC, as is true of all NRTIs, is of little use in 
developing a dosing schedule. Rather, it is the intracellular 
half-life of the nucleoside triphosphate that is the relevant 
parameter.
Kewn et al showed in a pharmacokinetic study using 
the 300 mg dose once daily dose in six patients that CBV-
TP levels remained above the inhibitory levels of the virus 
after 24 hours.7 Using the same method, Harris et al studied 
CBV-TP levels in peripheral mononuclear cells (PBMCs) of 
5 HIV-positive adults taking ABC 600 mg once a daily for 5 
to 17 months as a component of multiple drug rescue therapy. 
It was shown that the half life of CVB-TP was greater than 
12 hours.8 A slightly larger study than that done by Harris 
et al was carried out by Piliero et al involving twenty patients 
given ABC 300 mg dose over a 24-hour period. Results 
showed a mean PBMC intracellular half-life of 20.64 and 
mean plasma half-life of 2.59 hours respectively.6
Drusano et al9 using an in vitro pharmacodynamic model 
system, provided further support for once daily dosing. This 
group examined ABC dosing and ascertained the impact of 
the administration schedule on the activity of the drug. The 
antiviral effect and relationship to pharmacokinetics of a con-
tinuous infusion of ABC over 24 hours were compared with 
once-daily and twice-daily doses. A similar ABC exposure 
and antiviral effect was observed in all three regimens.
In an open-label, 2-period, crossover study, 34 HIV-
infected male and female subjects stabilized on antiretroviral 
regimens containing either ABC 600 mg onc daily or ABC 
300 mg twice daily by Moyle et al10 the intracellular CBV-TP 
values were similar, providing further pharmacokinetic 
support for the interchangeability of these two regimens.
Adverse events
A significant number of patients have poor adherence to anti-
retroviral medications secondary to intolerance and adverse 
effects. The most important adverse event associated with 
ABC is the ABC hypersensitivity reaction (ABC HSR). The 
ABC HSR is an idiosyncratic multiorgan clinical syndrome 
usually characterized by a sign or symptom in 2 or more of 
the following groups: (i) fever; (ii) rash; (iii) gastrointestinal: 
nausea, vomiting, diarrhea or abdominal pain; (iv) consti-
tutional: generalized malaise, fatigue or achiness; and (v) 
respiratory: dyspnea, cough, and/or pharyngitis. ABC HSR 
can be overlooked, as these symptoms may mimic various 
other disease conditions such as influenza, pneumonia, gas-
troenteritis. At one center, 15 HIV-positive patients who had 
symptoms of ABC HSR were compared with 30 HIV-positive 
patients who had symptoms of influenza.11 Gastrointestinal 
symptoms occurred in 60% of patients with ABC HSR versus 
6% of patients with influenza. Although fever and myalgia 
were commonly observed in both groups, rash occurred in 
47% of the patients with ABC HSR and in only 6% of patients 
with influenza. Although demographic characteristics, vital 
signs, and laboratory tests did not differ between the groups, 
respiratory symptoms that occurred without gastrointestinal 
symptoms were much more likely to be caused by influenza 
than by ABC HSR.Therapeutics and Clinical Risk Management 2010:6 85
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The overall incidence rate of ABC HSR is approximately 
8 % with some variability depending on genetic susceptibility of 
the population.12 More than 93% of ABC HSR reactions occur 
during the first 6 weeks of treatment.12–17 The median time to 
develop the reaction is 8 days. The reaction can develop on the 
first day of receipt of ABC therapy and has been reported to occur 
up to 160 days after initiation. Patients with a history of the ABC 
HSR who have been rechallenged with the drug have experienced 
unanticipated life-threatening consequences. Among 112 patients 
with ABC HSR who were rechallenged, an anaphylactic or 
immediate type of hypersensitivity reaction occurred in 20%.15 
Therefore, patients with clinically suspected ABC HSR should 
not be rechallenged. There have been case reports of patients 
who developed the ABC HSR after re-initiation of ABC after a 
hiatus in taking the medication, but this occurrence is believed 
to be rare.16 Interestingly, these patients had no symptoms of 
HSR during the first period of ABC administration. A study 
of 145 patients who interrupted ABC treatment showed 1 case of 
hypersensitivity but no statistical difference in incidence between 
the study patients who did not interrupt ABC.17
The ABC HSR is a clinical diagnosis. Physical findings 
associated with the ABC HSR in some patients include lymph-
adenopathy, mucous membrane lesions (conjunctivitis and 
mouth ulcerations), and rash. The rash usually is maculopapular 
or urticarial, but may be variable in appearance.18 Abnormal 
laboratory findings may occur, but they are no means specific 
or diagnostic. Eosinophilia usually is not present. Leukopenia, 
lymphopenia and thrombocytopenia may all occur.18 Approxi-
mately 10%–15% of cases have elevated liver enzymes and a 
rise in creatinine phosphokinase levels also has been reported.19 
Other abnormal laboratory values noted include elevations in 
alkaline phosphatase, blood urea nitrogen, serum creatinine, and 
lactic dehydrogenase levels. Disseminated intravascular coagu-
lation has also been reported as a manifestation of ABC HSR.20
A fever that develops within a few weeks after the initiation 
of therapy with abacavir may be due to causes other than hyper-
sensitivity. Most common is the likelihood that simultaneous 
initiation of treatment with drugs, such as trimethoprim–sulfa-
methoxazole, efavirenz, or nevirapine, may be the cause. The 
incidence of adverse reactions, including hypersensitivity, to 
each of these drugs is greater than that of ABC.21–23 The presence 
of gastrointestinal or respiratory symptoms that accompany a 
rash or fever suggest ABC HSR as the likely cause. Opportu-
nistic infections can manifest shortly after initiation of ARV 
as a result of immune reconstitution and should also be in the 
differential diagnosis.
Altered or unusual drug metabolism and a susceptible 
immune system are believed to be important cofactors for the 
development of drug-related hypersensitivity.24 HIV-infected 
persons are likely to be at special risk of developing hyper-
sensitivity reactions because of the disease associated 
perturbations in the immune system.25 Two members of a 
family who were treated with ABC both developed the HSR 
suggesting a genetic component to ABC HSR.26 Multiple 
studies have shown an association of the ABC HSR with 
HLA-B*5701.27–29 The use of this screening test to identify 
high risk patients has been shown by Rauch et al to reduce 
the occurrence of the ABC HSR.30 In this cohort involv-
ing more than 260 patients, the authors observed that the 
use of HLA-B*5701 screening decreased ABC HSR from 
7% to 1%. Similarly, the incidence of the ABC HSR 
decreased from 6.2% to 0.5% in a UK cohort of 185 patients 
treated with ABC using HLA screening.31
The PREDICT-1 trial, a double-blind, prospective, ran-
domized study involved 1956 patients from 19 countries, 
who were infected with human immunodeficiency virus type 
1 and who had not previously received abacavir evaluated 
the effectiveness of prospective HLA-B*5701 screening to 
prevent the hypersensitivity reaction to abacavir. The study 
found a significantly lower incidence of ABC HSR in the 
prospective-screening group (3.4%) than in the control group 
(7.8%), (P  0.001).32
Similar results were obtained from the SHAPE study 
further strengthening the utility of prescreening with the 
HLA-B*5701 test prior to starting abacavir.33
On the basis of these studies, the 2008 DHHS guidelines 
panel recommends screening for HLA-B*5701 before start-
ing patients on an abacavir-containing regimen, to reduce the 
risk of hypersensitivity reaction (AI recommendation).1
In an analysis of 5,332 patients enrolled in ABC clinical 
trials, being ART-experienced at the start of ABC therapy and 
being of African descent were associated with a nearly 40% 
reduction in the risk of hypersensitivity.19 Patients of white 
race were found to be at significantly greater risk in another 
study of a population with a low percentage of ethnic minori-
ties.14 Accumulated data suggest that factors that predict a 
lower likelihood to develop ABC HSR are: male sex, African 
racial origin, more advanced disease, and being an antiretro-
viral-experienced patient before initiation of ABC.12,14
There are no established interventions that will preempt 
the development of the ABC HSR. Patients randomized to 
receive prednisone 40 mg/day for the first 2 weeks when 
initiating ABC therapy in combination with nevirapine 
(NVP) and ZDV/3TC experienced a slightly higher incidence 
of hypersensitivity than those patients who did not receive 
prednisone (17% versus 10%, respectively).34Therapeutics and Clinical Risk Management 2010:6 86
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The decision whether to stop ABC therapy or to cautiously 
continue it is an important one when ABC HSR cannot 
clinically be excluded. For instance, a rash may occur dur-
ing ABC therapy without HSR. ABC may be an important 
component of an antiretroviral regimen that may be difficult 
to stop unless absolutely necessary because other alternatives 
may be lacking. However, the potential severity of ABC 
hypersensitivity calls for prudence. The overall case fatality 
rate is estimated to be 0.03%.19 ABC should be discontinued 
if the timing, severity, and combination of clinical symptoms 
are suggestive. When it is not clear if clinical symptoms are 
due to the ABC HSR, the drug may be continued under close 
clinical surveillance. For patients requiring hospitilzation 
due to ABC HSR, treatment is supportive.
In a recent large, prospective observational cohort of 
HIV infected individuals by the Data Collection on Adverse 
Events of Anti-HIV Drugs (DAD), the risk of myocardial 
infarction in relation to exposure to NRTI’s was studied.35 
DAD is an international collaboration of 11 cohorts, fol-
lowing 33,347 HIV-1-infected individuals at 212 clinics 
in Europe, the US, and Australia.6,7,23 All participants were 
under active follow-up in their cohorts at the time of enrol-
ment into DAD (December 1999 to January 2005). The 
study used Poisson regression models to quantify the relation 
between cumulative, recent (currently or within the preceding 
6 months), and past use of zidovudine, didanosine, stavudine, 
lamivudine, and abacavir and development of myocardial 
infarction. The study found no associations between the rate 
of myocardial infarction and cumulative or recent use of 
zidovudine, stavudine, or lamivudine. However recent use 
of abacavir or didanosine was associated with an increased 
rate of myocardial infarction (compared with those with no 
recent use of the drugs, relative rate 1.90, 95% confidence 
interval [CI] 1.47 to 2.45 [P = 0.0001] with abacavir and 1.49, 
1.14 to 1.95 [P = 0.003] with didanosine). After adjustment 
for predicted 10-year risk of coronary heart disease, recent 
use of both didanosine and abacavir remained associated with 
increased rates of myocardial infarction (1.49, 1.14 to 1.95 
[P = 0.004] with didanosine; 1.89, 1.47 to 2.45 [P = 0.0001] 
with abacavir). It was concluded that an increased risk of 
myocardial infarction exists in patients exposed to abacavir 
and didanosine within the preceding 6 months. This excess 
risk was not explained by underlying established cardiovas-
cular risk factors and was not present beyond 6 months after 
drug cessation.
The reproducibility of this finding in a different (but 
somewhat DAD-overlapping) dataset was explored and 
plausible biological mechanisms were sought by using the 
SMART study data. Biomarkers, ischemic changes on the 
electrocardiogram, and rates of various predefined types of 
cardiovascular disease (CVD) events according to NRTIs 
used were explored in the Strategies for Management of 
Anti-Retroviral Therapy (SMART) study.36 Patients receiv-
ing abacavir and not didanosine were compared with those 
receiving didanosine, and to those receiving NRTIs other than 
abacavir or didanosine (other NRTIs). Current use of abacavir 
was associated with an excess risk of CVD compared with 
other NRTIs. Adjusted hazard ratios for clinical myocardial 
infarction (n = 19), major CVD (myocardial infarction [MI], 
stroke, surgery for coronary artery disease, and CVD death 
n = 70); expanded CVD (major CVD plus congestive heart 
failure, peripheral vascular disease, coronary artery disease 
requiring drug treatment, and unwitnessed deaths n = 112); 
were 4.3 [95% CI 1.4 to 13.0], 1.8 (1.0 to 3.1), and 1.9 (1.3 
to 2.9). At baseline in a subset of patients with biomarker 
data, high sensitivity-C-reactive protein and interleukin-6 
were 27% (P = 0.02) and 16% (P = 0.02) higher for patients 
receiving abacavir (N = 175) compared with those receiving 
other NRTIs (N = 500). The analysis concluded that abacavir 
was associated with an increased risk of CVD and may cause 
vascular inflammation, which may precipitate a CVD event.
Analysis was performed by GlaxoSmithKline of Glaxo-
SmithKline-sponsored clinical trials with 24 weeks of 
combination antiretroviral therapy comprising 14,174 HIV-
infected adults who received ABC (n = 9502; 7641 person-
years) or not (n = 4672; 4267 person-years). The baseline 
demographics and HIV disease characteristics, including 
lipids and glucose values, were similar. MI rates were com-
parable among subjects exposed [n = 16 (0.168%; CI 0.096 to 
0.273; 2.09 per 1000 person-years)] or not [n = 11 (0.235%; 
CI 0.118 to 0.421; 2.57 per 1000 person-years)] to ABC-
containing therapy. In this analysis there were few MI events 
overall and no excess risk of MI with ABC therapy.37
A study conducted by Veterans Affairs investigators, 
involving 19,424 people with an average 3.9 years of follow-up, 
showed a slight, statistically non-significant increase in MI 
with abacavir.38 The association of ABC use with AMI was 
much weaker after adjusting for traditional cardiovascular risk 
factors, including chronic kidney disease (CKD). Predictably, 
a significantly higher number of patients with estimated glo-
merular filtration rate below 60 received abacavir compared to 
tenofovir (P  0.0001), which has been associated with acute 
kidney injury and worsening renal function.
We have to keep the possibility of channeling bias in 
interpreting the DAD study results, since patients with CKD 
are more likely to be prescribed abacavir than tenofovir and Therapeutics and Clinical Risk Management 2010:6 87
Abacavir/lamivudine combination for Hiv Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
CKD is a risk factor for MI, and the DAD study did not adjust 
for CKD. In addition, other studies, such as the AIDS Clinical 
Trials Group (ACTG) ALLRT observational cohort did not 
find an association of abacavir use with increased risk for 
myocardial infarction.39
Although there have been conflicting results in these 
studies, abacavir/lamivudine combination has now been 
moved to the alternative first line treatment category in treat-
ment naïve patients. Pending further studies, we should exer-
cise caution in using abacavir in treating HIV-infected patients 
with underlying high risk for cardiovascular disease.
Lamivudine (3TC)
Lamivudine is available as a single agent, in dual combina-
tion with abacavir (ABC/3TC or epzicom), and zidovudine 
(AZT/3TC or combivir), and in triple combination with 
zidovudine and abacavir (ABC/AZT/3TC or trizivir). The 
recommended adult dosage is 150 mg twice daily or 300 mg 
once daily orally in combination with other antiretroviral 
agents. The recommended dose in renal insufficiency (cre-
atinine clearance 30 to 50 mL/min) is 150 mg daily. For cre-
atinine clearance 15 to 29 mL/min, the dose is 100 mg daily, 
following a loading dose of 150 mg; for creatinine clearance 
5 to 14 mL/min, the dose is 50 mg daily, following a loading 
dose of 150 mg; for creatinine clearance 5 mL/min, the dose 
is 25 mg daily, following a loading dose of 50 mg.1 These 
dosing adjustments are based on achieving levels comparable 
to those in persons without renal impairment.
Chemistry and pharmacodynamics
Lamivudine (3TC) is a cytosine analogue. It undergoes 3-step 
phosphorylation like ABC to form the active metabolite 
lamivudine triphosphate (3TC-TP) which competes with 
endogenous cytosine. In the first step, deoxycytidine kinase 
catalyzes the formation of the monophosphate. In the sec-
ond step, the monophosphate is phosphorylated by cytidine 
monophosphate (deoxycytidine monophosphate kinase) to 
the diphosphate. Finally, the diphosphate is converted to the 
triphosphate by the enzyme nucleoside diphosphate kinase. 
After 3TC is triphosphorylated, the principle mode of action 
is inhibition of HIV reverse transcription via viral DNA chain 
termination. It should be pointed out that the phosphorylation 
pathways for 3TC and ABC are different.
Pharmacokinetics
3TC is rapidly absorbed after oral administration. The 
absolute bioavailability is approximately 82% in adults. The 
drug reaches a maximum concentration of 0.5 to 1.5 hours 
after oral administration. Less than 36% of the drug binds to 
plasma protein. The half life of elimination is 5 to 7 hours in 
adults but it is suitable to be administered as once daily dose 
as discussed in the next paragraph. Lamivudine is excreted 
primarily in the urine as unchanged drug.
In a study comparing the plasma pharmacokinetics of 
3TC administered 150 mg twice daily and 300 mg once 
daily orally in 13 HIV-1 infected patients, Bruno et al were 
able to show that although there was statistically significant 
differences (P  0.05) between the 2 schedules for Cmax and 
Cmin values, average concentration over the dosage interval 
and AUC over 2 dosage intervals (24 hours) were similar.40 
The investigators concluded that their results provided the 
pharmacokinetic basis for using 3TC in a once daily regi-
men. Similar to ABC, with lamivudine, it is the intracellular 
concentration of the active metabolite that determines its 
activity, efficacy and suitability for once daily dosing.
Moore et al evaluated the pharmacokinetics of 3TC 
phosphorylation in peripheral blood mononuclear cells from 
10 asymptomatic, antiretroviral-experienced HIV-1 infected 
patients who were receiving treatment with a regimen of 
3TC and zidovudine (ZDV).41 The patients were randomly 
assigned to receive 3TC 150 mg twice a day or 300 mg twice 
a day for 14 days. The median half-life of intracellular 3TC-
TP was 15.3 hours for the 150-mg dose and 16.1 hours for 
the 300-mg dose, a nonsignificant difference. Yuen et al42 
compared the steady-state pharmacokinetics of 3TC in 
plasma and the active metabolite 3TC-TP in PBMCs. In this 
study, 60 healthy subjects received 3TC 300 mg once daily 
for 7 days and 150 mg twice daily for 7 days. Steady-state 
plasma 3TC pharmacokinetics following the once- and twice-
daily regimens were bioequivalent with respect to both the 
AUC from 0 to 24 hours at steady state and average plasma 
3TC concentration at steady state over the dosing interval. 
Steady-state intracellular 3TC-TP pharmacokinetics after 
the once- and twice-daily regimens are bioequivalent with 
respect to AUC and average plasma concentrations, as well 
as maximal 3TC concentrations. Overall, the results of this 
study suggest that for key pharmacokinetic parameters, 3TC 
300 mg once daily is equivalent to 3TC 150 mg twice daily. 
A summary of the pharmacokinetic properties of ABC and 
3TC is as shown in Table 1.
Drug interactions
The combination of 3TC and ABC as an NRTI backbone is 
ideal and effective because there is no intracellular competi-
tion for phosphorylation of these drugs. Furthermore, 3TC 
pharmacokinetics are not significantly affected by ABC.17 Therapeutics and Clinical Risk Management 2010:6 88
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Due to low protein binding, drug–drug interactions are 
infrequent. As a class, the NRTIs are predominantly excreted 
by the renal tubular system and interactions with drugs 
metabolized primarily by the cytochrome P-450 system 
are not encountered frequently. However drugs influencing 
renal clearance or intracellular phosphorylation may cause 
interactions with all of the NRTIs.
The main interaction of 3TC and other drugs occurs with 
drugs that use renal tubular excretion for their elimination. In a 
randomized 2-way cross over study,43 14 HIV-positive patients 
were given a 300 mg single dose 3TC and trimethoprim/
sulfamethoxazole (TMP/SMX) 160/800 mg for 5 days. It was 
noted that the area under the curve (AUC) of 3TC increased 
by 43%, and renal clearance of 3TC decreased by 30%. This 
increase was considered not significant, especially given the 
favorable safety profile of lamivudine. No significant change 
in any pharmacokinetic parameter occurred for TMP/SMX. 
Thus, no 3TC dosage adjustment is needed when used with 
TMP/SMX.
Lamivudine and zalcitabine (ddC) may inhibit the intra-
cellular phosphorylation of one another and therefore such 
combination in any drug regimen should be avoided.18 In vitro 
data indicate that ribavirin reduces phosphorylation of 3TC, 
stavudine (d4T) and AZT. However, no pharmacokinetic or 
pharmacodynamic interaction was observed when ribavirin 
and 3TC (n = 18), d4T (n = 10), or AZT (n = 6) were co-
administered as part of a multi-drug regimen to HIV/HCV 
co-infected patients.18
There have been concerns about possible pharmaco-
kinetic interaction between ABC and ethanol, as both are 
metabolized by alcohol dehydrogenase. However, in an open 
labeled randomized, 3- way crossover, phase 1 study, 24 HIV-
positive males were given alcohol 0.7 g/kg and a single dose 
of 600 mg ABC. It was shown that ABC AUC increased by 
41%, half-life of elimination increased by 26 %, and plasma 
maximum concentration increased by 15%. These changes 
were not considered statistically significant.18,44
In a study of 11 HIV infected patients receiving 
methadone-maintenance therapy (40 mg and 90 mg daily) 
with 600 mg of ABC twice daily (twice the currently rec-
ommended dose), oral methadone clearance increased by 
22% (90% Cl = 6%–42%). This alteration will not result in 
a methadone dose modification in the majority of patients; 
however, an increased methadone dose may be required in a 
small number of patients.18 Lamivudine does not affect the 
clearance of methadone.
Both lamivudine and abacavir are listed as Pregnancy 
Category C drugs. No well-controlled trials of the FDC of 
abacavir + lamivudine (Kivexa®/Epzicom®) have been con-
ducted in pregnant women. The drugs should be used in 
pregnancy only when the benefits outweigh the risks.18
Clinical efficacy studies
ABC/3TC combination in comparison 
to other nucleotide combinations
CNA30024 study,45 a multicenter, randomized, double-
blind trial compared the efficacy and safety of ABC/3TC 
versus AZT/3TC combined with efavirenz (EFV) in 649 
antiretroviral-naive HIV-infected patients. Baseline median 
HIV-1 RNA level was 4.79 log10 copies/mL (39% of patients 
had HIV-1 RNA levels  100,000 copies/mL). Baseline 
median CD4+ cell count was 264 cells/mL. Participants were 
randomized to receive either a 300-mg tablet of ABC and a 
placebo tablet, both administered twice daily, or a 300-mg 
tablet of AZT and a placebo tablet, both administered twice 
daily. All participants received a 150-mg tablet of 3TC twice 
daily plus 600 mg of EFV once daily. The primary objective 
was a comparison of the proportion of patients achieving 
plasma HIV-1 RNA levels (VL) 50 copies/mL through 
Table 1 Pharmacokinetics of abacavir (ABC) and lamividine (3TC) in adults
Pharmacokinetic property ABC 3TC
Oral bioavailability (%) 83 82–86
Cmax (mg/ml) 4.26 2.04
Mean time to Cmax (hours) 0.7–1.7 0.5–1.5
AUC (mg *h/mL) 11.95 8.87
Plasma protein binding (1%) 50 36
Plasma T1/2 (hours) 1.5 5–7
intracellular T1/2 (hours) 20.64 16–19
Metabolism Predominantly hepatic metabolism and then 
renal excretion (about 83%); 2% of the drug 
renally excreted as unchanged drug
5%–10% hepatic metabolism; predominantly 
renal excretion as unchanged drug via 
organic cationic transportationTherapeutics and Clinical Risk Management 2010:6 89
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week 48 of the study. At week 48, 70% of patients in the ABC 
group, compared with 69% in the AZT group, maintained 
a confirmed VL of 50 copies/mL (in the ITT exposed 
population). There was a significantly different CD4+ cell 
increase from baseline at 48 week: 209 cells/mm3 in the ABC 
group versus 155 cells/mm3 in the AZT group (P = 0.005). 
Although both groups had similar baseline CD4+ cell counts, 
the ABC group showed a better median absolute CD4+ cell 
response at all time points observed. The most common 
reported adverse effect in the AZT arm was nausea (37% 
versus 23% in the ABC arm). Reasons for discontinuation of 
drug in the ABC arm included nausea (2%), dizziness (1%), 
rash (3%) and suspected ABC HSR (8%); in the AZT arm, 
nausea, dizziness, rash (3% each) and anemia (4%) were the 
most common reasons for drug discontinuation.
The NRTI sub study of the FIRST study46 randomized 
182 antiretroviral-naïve participants to receive abacavir + 
lamivudine versus didanosine + stavudine, each combined 
with a PI, an NNRTI, or both. Mean HIV RNA and CD4+ cell 
counts at baseline were 5.1 log10 copies/mL and 212 cells/mm3. 
After a median follow-up of 28 months, there was no differ-
ence in rates of HIV RNA  50 copies/mL between the two 
NRTI groups. However, there was a trend (0.05  P  0.10) 
for the abacavir + lamivudine group to be better than the 
didanosine + stavudine group for HIV RNA decreases, CD4+ 
cell count increases, and tolerability. The combination of 
didanosine + stavudine is no longer recommended, due to 
excessive toxicity observed in multiple clinical trials.1
A5202 was a phase IIIB, randomized 4-arm study for 
treatment-naïve subjects of double-blind ABC/3TC vs TDF/
FTC with open-label efavirenz or atazanavir + ritonavir, strat-
ified by screening HIV RNA ( vs 100,000 copies/mL).47 
The primary endpoints were time to virologic failure (VF) 
(confirmed HIV RNA  1000 copies/mL at 16 to 24 weeks 
or 200 cells/mL at 24 weeks) and time to first Grade 3/4 
adverse event (AE). A5202 enrolled 1858 eligible subjects; 
797 had screening HIV RNA  100,000 copies/mL. Median 
follow-up was 60 weeks. 85% were men, 26% Black, 25% 
Hispanic; mean baseline HIV RNA = 5.1 log10 copies/mL, 
CD4 = 181/mm3. Among participants with entry HIV 
RNA  100,000 copies/mL, time to VF was significantly 
shorter in the ABC/3TC than TDF/FTC arm (HR = 2.33, 
95% CI 1.46 to 3.72, P = 0.0003), occurring in 57 and 26 
subjects respectively. In a secondary cross-sectional analysis 
(prior VF and regimen changes included), the proportion 
(95% CI) with HIV RNA 50 copies/mL at week 48 was 
75% (69% to 80%) for ABC/3TC and 80% (74% to 85%) 
for TDF/FTC (P = 0.20). Subjects receiving ABC/3TC had 
a shorter time to grade 3/4 AEs (HR = 1.87, 95% CI 1.43 to 
2.43, P  0.0001), predominantly general body aches and 
lipid increases. The comparisons of  blinded NRTIs in the 
lower HIV RNA stratum and each regimen’s third drug in 
both strata are ongoing. Data safety monitoring board review 
prompted unblinding of NRTIs, additional analyses and rec-
ommendations to continue with NRTIs of choice due to the 
significant virologic efficacy differences by NRTIs for sub-
jects with screening HIV RNA 100,000 copies/mL.
The HEAT study was the first completed, randomized 
clinical trial to directly compare the efficacy, safety, and tol-
erability of these agents, each in combination with lopinavir/
ritonavir in antiretroviral-naive patients. Six hundred and 
eighty-eight antiretroviral-naive, HIV-1-infected patients were 
randomized in this double-blind, placebo-matched, multi-
center, non-inferiority study to receive a once-daily regimen of 
either ABC/3TC 600 mg/300 mg or  TDF/FTC 300 mg/200 mg, 
both with lopinavir/ritonavir 800 mg/200 mg. Primary end-
points were the proportion of patients with HIV-1 RNA below 
50 copies/mL at week 48 (missing = failure, switch included 
analysis) and the proportion of patients experiencing adverse 
events over 96 weeks. At week 48, 68% in the ABC/3TC group 
vs. 67% in the TDF/FTC group achieved an HIV-1 RNA 
below 50 copies/mL (intent-to-treat exposed missing = failure, 
95% confidence interval on the difference -6.63 to 7.40, 
P = 0.913), demonstrating the non-inferiority of ABC/3TC 
to TDF/FTC at week 48. Non-inferiority of the two regimens 
was sustained at week 96 (60% versus 58%, respectively, 95% 
confidence interval -5.41 to 9.32, P = 0.603). In addition, 
efficacy of  both regimens was similar in patients with baseline 
HIV-1 RNA  100,000 copies/mL or CD4 cell counts below 
50 cells/mL. In this analysis, both ABC/3TC and TDF/FTC 
provided comparable antiviral efficacy, safety, and tolerability 
when each was combined with lopinavir/ritonavir in treatment-
naive patients.48
Only 2 studies are available comparing the ABC/3TC 
and TDF/FTC combinations head-on, with 1 (A5202) still 
not completed. Conflicting results were noted between 
both studies in terms of virologic failure and pending 
further studies, caution should be exercised in using 
abacavir/lamivudine in treatment naïve patients with base-
line RNA  100,000 cm3/mL.
ABC/3TC as separate agents combined 
with a Pi or NNRTi
The NEAT trial49 was an international, multicenter, random-
ized, open-label study that compared the efficacy, durabil-
ity, and tolerability of unboosted fos-amprenavir (f-AMV) Therapeutics and Clinical Risk Management 2010:6 90
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1400 mg twice daily, with nelfinavir (NFV) 1250 mg twice 
daily, in antiretroviral therapy (ART)-naive HIV-infected 
adults with plasma viral load at screening greater than or 
equal to 5000 copies/mL. Patients were randomly assigned 
to f-AMV or NFV (2:1) for a minimum of 48 weeks, with a 
background of ABC and 3TC. A total of 166 patients were 
on the f-AMV arm and 83 on the NFV arm. Most of the 
patients in the study had a previous CDC class C event. At 
the time of enrollment, the median HIV RNA level was 4.82 
to 4.85 log10 copies/mL and median CD4+ count was 212 to 
214 cells/mm3. After 48 weeks of study, favorable virologic 
and immunologic responses were observed for both groups. 
The ABC/3TC backbone combined with either f-AMV or 
NFV was well- tolerated.
The SOLO study50 compared the magnitude and durability 
of the antiviral response to ritonavir-boosted fos-amprenavir 
(f-AMV/r) with NFV , each administered with ABC and 3TC. 
This was a randomized, open label-study in antiretroviral 
therapy-naïve advanced HIV+ patients. Three hundred and 
twenty patients received f-AMV/r (1400/200 mg) once daily 
and 327 patients received NFV 1250 mg twice daily; both 
groups received the ABC/3TC backbone given twice daily. 
Median CD4+ cell count was 170 cells/mm3 and median 
HIV RNA level was 4.78 log10 copies/mL. At week 48, the 
f-AMV/r arm was noninferior to the NFV arm. Sixty-nine 
percent of patients in the f-AMV/r group and 68 % in the 
NFV group had HIV RNA levels  400 copies/mL; 55% of 
patients in the f-AMV/r group and 53 % in the NFV group 
had HIV RNA levels  50 copies/mL. Diarrhea was the 
only adverse event to be statistically significantly different in 
incidence between treatment groups (16% for NFV versus 
9% for f-AMV/r; P = 0.008).
The ZODIAC study51 evaluated the efficacy and safety 
of once daily versus twice daily doses of ABC. This was a 
randomized double-blind study. Patients received 600 mg 
once daily (n = 384) versus 300 mg administered twice daily 
(n = 386) in combination with 300 mg 3TC and 600 mg of 
EFV each administered once daily in antiretroviral-naive 
patients over 48 weeks. The baseline median plasma HIV-1 
RNA level was 4.89 log10 copies/mL (44% of  the patients had 
viral load 100,000 copies/mL at baseline); median CD4+ 
cell count was 262 cells/mm3. ABC administered once daily 
was non-inferior to the twice-daily regimen, with 66% and 
68% of patients in these respective treatment arms achiev-
ing a confirmed plasma HIV-1 RNA level  50 copies/mL 
at 48 weeks. The ABC once-daily and twice-daily regimens 
were similar with respect to infrequency of virologic failure 
(10% vs 8%), emergence of resistance mutations, CD4+ cell 
count increases from baseline, safety profile, and incidence 
of ABC-related hypersensitivity reactions (9% versus 7%).
The CLASS study52 was an open-label, multicenter, 
randomized trial of up to 3 consecutive treatment regimens 
over 96 weeks. Two hundred ninety-one subjects received an 
ABC/3TC backbone with either efavirenz (NNRTI, n = 97), 
ritonavir-boosted amprenavir (PI, n = 96), or stavudine 
(NRTI, n = 98). Participants receiving boosted amprenavir 
(APV/r) were later switched to boosted fos-amprenavir 
(f-AMV/r) to decrease bill burden. At week 96, there were no 
statistically significant differences between arms in the per-
centages of subjects with HIV RNA levels  50 copies/mL 
by ITT analysis (missing data = failure): 68%, 58%, 61% 
on EFV, APV/r and d4T arms, respectively. The NNRTI 
arm had a statistically significantly greater percentages of 
participants with HIV RNA levels  50 copies/mL at weeks 
24 (P = 0.018) and 48 (P = 0.047). Twenty-one subjects had 
HSR attributed to ABC (7.3%). In conclusion, all treatment 
regimens demonstrated excellent 96-week results. Second-
ary analyses favored the NNRTI regimen over the PI and 
NRTI regimens.
ABC/3TC fixed dose as backbone 
in studies comparing Pi versus NNRTi
The KLEAN (Kaletra versus Lexiva with Epivir and Abacavir 
in ART-Naïve patients) study53 compared ritonavir-boosted 
lopinavir (LPV/r) to ritonavir-boosted f-AMV/r combined 
with an ABC/3TC fixed-dose combination backbone. This 
was an open-label, non-inferiority study. Eight hundred 
seventy-eight antiretroviral-naive, HIV-1-infected persons 
were randomized to receive either f-AMV/r 700 mg/100 mg 
twice daily or LPV/r 400 mg/100 mg twice daily, each with 
ABC/3TC 600 mg/300 mg once daily. At week 48, noninfe-
riority of f-AMV/r to LPV/r was shown, with 73% patients 
in the f-AMV/r group and 71% in the LPV/r group achieving 
HIV-1 RNA levels  400 copies/mL. Treatment discontinu-
ations due to an adverse event were few and occurred with 
similar frequency in the two treatment groups. The ABC 
HSR occurred in 6% of persons on the f-AMV/r arm versus 
4% on the LPV/r arm.
In the ESS30008 study,54 ABC and 3TC administered 
twice daily were compared with fixed-dose combination 
(FDC) ABC/3TC administered once daily, both with either a 
PI or NNRTI in ARV-experienced persons. Two hundred sixty 
HIV-infected subjects with more than 6 months of ABC and 
3TC administered twice daily plus a PI or NNRTI with an 
HIV RNA level  400 copies/mL for  3 months and a CD4+ 
cell count  50 cells/mm3 were randomized 1:1 to continue Therapeutics and Clinical Risk Management 2010:6 91
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ABC/3TC administered twice daily or switch to the FDC 
ABC/3TC administered once daily. At baseline, median time 
on ABC and 3TC administered twice daily was 22 months, 
and median CD4+ cell count and HIV RNA level were 
554 cells/mm and 50 copies/mL, respectively. ABC/3TC 
FDC administered once daily was established as not inferior 
to ABC/3TC administered twice daily based on the propor-
tion of nonvirologic failures. Proportions of persons in each 
group with an HIV-1 RNA level  50 copies/mL were 81% 
(ABC/3TC FDC) and 82% (ABC + 3TC BID) at week 48 
by ITT (missing data = failure). Virologic failure was rare 
(2 patients taking the once-daily regimen, 4 patients taking 
the twice-daily regimen). There was a low incidence of 
grade 2 through 4 adverse events and no drug-related serious 
adverse events or hypersensitivity reactions seen.
The CAL30001 study5 was a randomized, open-label 
study to compare the efficacy and safety of ABC/3TC FDC 
administered once daily to ABC (administered twice daily) 
and 3TC (administered once daily) given as separate entities, 
in combination with tenofovir (NRTI) and a new PI or NNRTI 
in antiretroviral-experienced adults experiencing VF defined 
as a VL  1000 copies/mL at the time of enrollment with 3 or 
fewer NRTI-associated mutations. The primary efficacy end 
point was the time-averaged change from baseline (average 
area under the curve minus baseline) in plasma HIV RNA 
over 48 weeks. A total of 186 subjects were enrolled. No 
significant differences were seen in the primary efficacy 
endpoint or in the percentage of participants who achieved 
an HIV RNA level  50 copies/mL. Tolerability was similar 
between the 2 groups.
Monotherapy with fixed dose combination of abacavir/ 
lamivudine/zidovudine (trizivir) is not considered standard 
of care for initial therapy due to inferior virologic efficacy,55 
compared to a regimen containing a drug from another class 
(efavirenz).
Safety, tolerability and adverse effects
As previously discussed, neither ABC nor 3TC is metabo-
lized by the CYP-450 system. Consequently, drug–drug 
interactions are limited. Nucleoside analogs are associated, 
by varying degrees, with mitochondrial dysfunction. This 
toxicity can result in dyslipidemia, lipoatrophy and lactic 
acidosis. Lactic acidosis results from the inhibition of mito-
chondrial DNA synthesis by the nucleoside analogs, result-
ing in anaerobic glycolysis and intracelluar accumulation 
of lactate. 3TC has greater affinity for mitochondrial DNA 
than does ABC.56,57 In vitro data have shown that neither 3TC 
nor ABC is associated with hepatic cytotoxicity or depletion 
of mitochondrial DNA.58 Furthermore, in a cohort study 
evaluating the risk factors for hyperlactatemia and lactic 
acidosis, ABC/3TC was associated with the lowest relative 
risk amongst NRTI pairs in the trial.59 The combination of 
ABC + 3TC also has been shown to have minimal or no 
effects on in terms of lipoatrophy as well as favorable lipid 
insulin and other metabolic effects.60–62 Replacing stavudine 
with abacavir or zidovudine has been shown to improve 
stavudine-induced lipoatrophy.63
Resistance
ABC selects for mutations at positions 65 (K65R), 74 (L74V), 
115 (Y115F), and 184 (M184V) in reverse transcriptase 
(RT). Lamivudine selects for mutations only at position 
184 (M184/V/I) in RT.64 The M184V/I mutations confers 
substantial resistance to both 3TC and emtricitabine, but 
only about a 2- to 3-fold increase in IC50 to abacavir. Thus, an 
isolated M184V/I mutation does not result in complete loss 
of activity to abacavir. In addition, the M184V/I mutations 
may enhance susceptibility to zidovudine, stavudine, and 
tenofovir.64 Furthermore, the presence of the M184V/I muta-
tion typically results in impaired viral replication capacity, 
which has been shown to decrease HIV RNA levels by about 
0.5 logs.65,66 When ABC + 3TC are used in combination with 
another class, the M184V mutation typically appears first and 
most frequently; the K65R mutation and L74V mutation are 
seen much less frequently. The abacavir-selected mutations 
K65R, L74V and Y115F each individually confer about 
three-to fourfold resistance to ABC, but in combinations of 
2 or 3, they confer up to 8- to 10-fold resistance.67
The thymidine analogue mutations (TAMs), which include 
M41L, D67N, L210W and T215Y/F, K219Q/E/N, are not 
selected by ABC but rather by the thymidine analogues ZDV 
and d4T. These mutations are associated with cross-resistance 
to all NRTIs, with increasing resistance as more of the TAMs 
accumulate. In isolation, they are associated with low-level 
resistance to 3TC and reduced virologic response to ABC. 
Patients with four TAMs in combination with M184V and 
L74V have minimal virologic responses to ABC-based regi-
mens.68,69 Other mutations conferring high-level resistance to 
both ABC and 3TC in combination with TAMs are the T69 
insertion mutation and the presence of E44D plus V1181. The 
Q151M complex also results in resistance to both drugs.70
Conclusion and expert opinion
ABC/3TC is a well tolerated and effective NRTI back-
bone for both ARV-naive and ARV-experienced patients. 
The combination has been well studied and proven to Therapeutics and Clinical Risk Management 2010:6 92
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be efficacious in multiple studies. The flexibility of using 
this NRTI backbone with other classes is an additional 
advantage. Resistance mutations have not limited the clini-
cal utility of  this combination when used with other classes. 
The availability of the drugs in both FDC and individual 
formulations gives physicians the additional flexibility of 
dose adjustment when required. Other advantages of this 
combination are the relative paucity of significant drug-
drug interactions and the option to take the medication with 
or without food. However, all patients should be screened 
for HLA-B5701, prior to initiating treatment with ABC 
to prevent the occurrence of abacavir-hypersensitivity 
syndrome. Recent studies, albeit with conflicting results, 
have suggested a possible increased risk of myocardial 
infarction. One recent study showed a shortened duration 
to virologic failure in patients with pre-treatment HIV 
RNA  100,000 cm3/mL. Pending further studies, caution 
should be exercised in patients with underlying risk factors 
for CAD and baseline VL  100,000 cm3/mL. In patients 
without these risk factors and a negative HLA-B5701 
screen, the abacavir/lamivudine combination is a suit-
able alternative especially in patients with renal disease 
and contraindications to tenofovir.
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